{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:20:32Z","timestamp":1771654832749,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.lrr.2023.100409","type":"journal-article","created":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T02:32:56Z","timestamp":1703903576000},"page":"100409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Avapritinib treatment of aggressive systemic mastocytosis with a novel KIT exon 17 mutation"],"prefix":"10.1016","volume":"21","author":[{"given":"Lyndsey","family":"Sandow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajia","family":"Town","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C.","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lrr.2023.100409_bib0001","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.lrr.2023.100409_bib0002","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The5th editionof the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.lrr.2023.100409_bib0003","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","article-title":"Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay","volume":"13","author":"Kristensen","year":"2011","journal-title":"J. Mol. Diagn."},{"issue":"7","key":"10.1016\/j.lrr.2023.100409_bib0004","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.lrr.2023.100409_bib0005","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2019000932","article-title":"New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis","volume":"135","author":"Reiter","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lrr.2023.100409_bib0006","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"KIT mutation analysis in mast cell neoplasms: recommendations of the European competence network on mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.lrr.2023.100409_bib0007","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lrr.2023.100409_bib0008","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.lrr.2023.100409_bib0009","doi-asserted-by":"crossref","first-page":"e43090","DOI":"10.1371\/journal.pone.0043090","article-title":"Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis","volume":"7","author":"Traina","year":"2012","journal-title":"PLoS One"},{"issue":"24","key":"10.1016\/j.lrr.2023.100409_bib0010","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1182\/blood-2011-12-397588","article-title":"In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells","volume":"120","author":"Soucie","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.lrr.2023.100409_bib0011","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.6004\/jnccn.2018.0088","article-title":"Systemic mastocytosis, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"16","author":"Gotlib","year":"2018","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"26","key":"10.1016\/j.lrr.2023.100409_bib0012","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.lrr.2023.100409_bib0013","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.lrr.2023.100409_bib0014","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat. Med."},{"issue":"414","key":"10.1016\/j.lrr.2023.100409_bib0015","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao1690","article-title":"A precision therapy against cancers driven by KIT\/PDGFRA mutations","volume":"9","author":"Evans","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.lrr.2023.100409_bib0016","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/bjh.16092","article-title":"Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies","volume":"187","author":"Weisberg","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.lrr.2023.100409_bib0017","article-title":"Targeting kinases with precision","volume":"5","author":"Gardino","year":"2018","journal-title":"Mol. Cell Oncol."},{"issue":"4","key":"10.1016\/j.lrr.2023.100409_bib0018","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/17843286.2022.2137631","article-title":"Mastocytosis and related entities: a practical roadmap","volume":"78","author":"Beyens","year":"2023","journal-title":"Acta Clin. Belg."},{"issue":"6","key":"10.1016\/j.lrr.2023.100409_bib0019","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/humu.22981","article-title":"HGVS recommendations for the description of sequence variants: 2016 Update","volume":"37","author":"den Dunnen","year":"2016","journal-title":"Hum. Mutat."},{"issue":"D1","key":"10.1016\/j.lrr.2023.100409_bib0020","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2018","journal-title":"Nucleic. Acids. Res."},{"issue":"1","key":"10.1016\/j.lrr.2023.100409_bib0021","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop Mutant KIT isoforms associated with human malignancies","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048923000493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048923000493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T02:09:17Z","timestamp":1718935757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048923000493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":21,"alternative-id":["S2213048923000493"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2023.100409","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avapritinib treatment of aggressive systemic mastocytosis with a novel KIT exon 17 mutation","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2023.100409","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100409"}}